Pfizer (NYSE:PFE) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Pfizer (NYSE:PFE) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13, Zacks reports. The company had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.87 EPS.

Pfizer Trading Up 0.0%

PFE traded up $0.01 during mid-day trading on Tuesday, hitting $30.68. The stock had a trading volume of 8,221,655 shares, compared to its average volume of 39,555,352. The stock’s fifty day simple moving average is $28.60 and its 200-day simple moving average is $26.82. The firm has a market capitalization of $174.85 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 2.00 and a beta of 0.32. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.06. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.6%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. Cantor Fitzgerald lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Scotiabank increased their price target on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Five research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.65.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Quarterly results exceeded expectations. Pfizer reported third-quarter adjusted earnings of $0.87 per share, above analyst estimates ranging from $0.72 to $0.74. Revenue of $16.58 billion also surpassed the approximately $15.85 billion consensus, although it was essentially flat year over year. Pfizer Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Pfizer raised its full-year 2026 revenue and adjusted EPS outlook. Management cited strong year-to-date performance, cost reductions and commercial momentum. Demand for Eliquis, the company’s blood thinner, was specifically identified as a key driver. Pfizer Raises 2026 Forecast on Strong Demand for Eliquis
• Positive Sentiment: Growth is broadening beyond COVID products. Newly launched and acquired products reportedly grew 32% in the quarter, helping offset weaker vaccine and treatment sales and supporting the view that Pfizer’s pipeline and portfolio can generate post-pandemic growth. Pfizer Raises Forecast on Momentum With New Products
• Neutral Sentiment: Cecile Guegan was appointed permanent chief financial officer. The company veteran had served as interim CFO since August and brings familiarity with Pfizer’s finances and strategy, reducing transition risk but representing continuity rather than a major strategic change. Pfizer Appoints Cecile Guegan as Chief Financial Officer
• Negative Sentiment: Underlying revenue remains pressured. Third-quarter sales were down slightly from the prior year, and declining COVID-19 vaccine and treatment revenue continues to weigh on comparisons. Additionally, after a recent rally toward a 52-week high, some investors may question whether the earnings and guidance improvements are already reflected in the stock. Pfizer Just Gained 12 Percent in a Month

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.